
Electromed (ELMD) Stock Forecast & Price Target
Electromed (ELMD) Analyst Ratings
Bulls say
Electromed Inc. demonstrated robust homecare revenue growth of 14.8% to $14.1 million, driven by enhanced sales rep productivity and effective demand generation initiatives. The company has established a solid foothold in the domestic homecare market, with distributor and hospital sales increasing significantly by 41% and 52%, respectively, indicating strong market traction. Although SG&A expenses rose by 17.2% due to strategic investments in personnel to bolster sales, marketing, and reimbursement efforts, these expenditures reflect a commitment to long-term growth and expansion into acute and international markets.
Bears say
Electromed Inc. faces a challenging outlook due to margin compression, competitive pressures, and decreased productivity among sales representatives, which could hinder growth potential. Additionally, any delays in the anticipated contributions from Pain Management and Wound Care could adversely affect expected growth rates and profit margins. These factors, combined with a significant decline in share price from a high of $35.43 to around $18, underscore the vulnerability of Electromed's financial performance.
This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.
Electromed (ELMD) Analyst Forecast & Price Prediction
Start investing in Electromed (ELMD)
Order type
Buy in
Order amount
Est. shares
0 shares